Answers are grounded in this paper and cite their sources.
STUDY AIMS: Clostridioides difficile infection (CDI) is associated with high recurrence and mortality. Faecal microbiota transplantation (FMT) is recognised as the most effective treatment for recurrent CDI. However, implementation varies internationally, and real-world data from Switzerland - where FMT is now regulated as a medicinal product - are scarce. Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, established a standardised FMT programme in 2019, yet its outcomes have not previously been reported. PATIENTS AND METHODS: This retrospective cohort study evaluated all adult patients treated with FMT for recurrent Clostridioides difficile (CDI) infection at CHUV between January 2021 and February 2025. Standardised procedures included strict donor screening, frozen preparation of stool suspensions or capsules, and administration by colonoscopy, jejunostomy, enema or oral capsules. The primary efficacy endpoint was clinical cure, defined as no CDI recurrence at 8 weeks. Adverse events and serious adverse events were recorded prospectively, with causality assessed according to international criteria. RESULTS: Among the 88 patients who received 100 FMTs, a clinical cure was achieved in 93% of cases after a single treatment, 98% after two and 100% after three. Only three new episodes were reported beyond the 8-week time point. Efficacy was consistent across subgroups, including immunosuppressed individuals. Early gastrointestinal adverse events were mild and transient. Of 24 serious adverse events recorded during follow-up, most were infections or complications related to underlying conditions. Eight deaths occurred during follow-up. Importantly, no serious adverse events or deaths were attributed to FMT. CONCLUSION: FMT demonstrated a high efficacy and a favourable safety profile for recurrent Clostridioides difficile infection in a real-world Swiss cohort, consistent with international evidence. Standardised donor selection, treatment production and pharmacovigilance were key to maintaining safety. These findings support FMT as a reliable therapeutic option for recurrent Clostridioides difficile infection, including high-risk populations. Further trials are warranted to evaluate earlier use of FMT in the CDI disease course.
No takes yet. Share an insight, caveat, or question.
Moser et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: